Business

China suspends Bristol-Myers’ most cancers drug over findings at U.S. plant

(Reuters) – China has suspended sale, import and use of Bristol-Myers Squibb Co’s cancer drug, Abraxane, the U.S. drugmaker’s China marketing partner said on Wednesday.

The suspension by China National Medical Products Administration is based on inspection findings at Bristol-Myers’ contract manufacturing facility in the United States, partner Beigene Ltd said.

Beigene and Bristol-Myers were working to restore supply as soon as possible, said the China-based drugmaker, which signed an agreement with Bristol-Myers’ Celgene unit in 2017 to market and distribute Abraxane.

Along with remediation efforts, Bristol-Myers has applied for approval to source its supply of Abraxane for the China market from an alternative manufacturing facility, Beigene said.

(Reporting by Manas Mishra in Bengaluru; Editing by Vinay Dwivedi and Shinjini Ganguli)

Read More: https://www.kbcchannel.tv | For More Business Articles | Visit Our Facebook & Twitter @kbcchanneltv | Making The Invisible, Visible


Source link

READ  Poundland sells 40,000 engagement rings forward of Valentine's Day

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Back to top button
Close
Close

Adblock Detected

Please consider supporting us by disabling your ad blocker
%d bloggers like this: